Showing 1 - 3 results of 3 for search 'Per Øyvind Enger', query time: 0.03s Refine Results
  1. 1
    Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma.

    Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. by Jian Wang, Agnete Svendsen, Justyna Kmiecik, Heike Immervoll, Kai Ove Skaftnesmo, Jesús Planagumà, Rolf Kåre Reed, Rolf Bjerkvig, Hrvoje Miletic, Per Øyvind Enger, Cecilie Brekke Rygh, Martha Chekenya

    Published 2011-01-01
    Get full text
    Article
  2. 2
    Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma.

    Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma. by Cecilie Brekke Rygh, Jian Wang, Marte Thuen, Andrea Gras Navarro, Else Marie Huuse, Frits Thorsen, Aurelie Poli, Jacques Zimmer, Olav Haraldseth, Stein Atle Lie, Per Øyvind Enger, Martha Chekenya

    Published 2014-01-01
    Get full text
    Article
  3. 3
    Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival

    Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival by Andrea Gras Navarro, Heidi Espedal, Justin Vareecal Joseph, Laura Trachsel-Moncho, Marzieh Bahador, Bjørn Tore Gjertsen, Einar Klæboe Kristoffersen, Anne Simonsen, Hrvoje Miletic, Per Øyvind Enger, Mohummad Aminur Rahman, Martha Chekenya

    Published 2019-07-01
    Get full text
    Article

Search Tools: